138 related articles for article (PubMed ID: 11789028)
1. Octreoscan SPET evaluation in the diagnosis of pancreas neuroendocrine tumors.
Briganti V; Matteini M; Ferri P; Vaggelli L; Castagnoli A; Pieroni C
Cancer Biother Radiopharm; 2001 Dec; 16(6):515-24. PubMed ID: 11789028
[TBL] [Abstract][Full Text] [Related]
2. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
[TBL] [Abstract][Full Text] [Related]
3. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
[TBL] [Abstract][Full Text] [Related]
4. [Indium-111-DTPA-phenyl-pentetreotide somatostatin receptors' scintigraphy in the evaluation of patients with suspected gastro-entero-pancreatic tumors. Comparison with computerized tomography].
Gerasimou GP; Aggelopoulou T; Papanastasiou E; Konidari-Dedousi E; Prousalidis I; Psarrakos K; Siountas A; Molybda E; Gotzamani-Psarrakou A
Hell J Nucl Med; 2007; 10(3):209-14. PubMed ID: 18084669
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Jamar F; Fiasse R; Leners N; Pauwels S
J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
[TBL] [Abstract][Full Text] [Related]
6. Whole body and tomographic scan with 111In-pentetreotide: preliminary data.
Gregianin M; Macrì C; Bui F; Varotto L; Zucchetta P
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):124-6. PubMed ID: 9002769
[TBL] [Abstract][Full Text] [Related]
7. Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors.
Usmani S; Khan HA; Abdulla M; Ahmed N; abu Huda F; Marafi F; al Kandari F; al Mohannadi S; al Nafisi N
Med Princ Pract; 2011; 20(4):356-61. PubMed ID: 21576997
[TBL] [Abstract][Full Text] [Related]
8. Role of (111)In-DTPA-pentetreotide scintigraphy in accurate diagnosis of neuroendocrine gastroenteropancreatic tumors.
Ichijo T; Ishikawa M; Shimojo M; Tsubuku M; Tsuboi K; Miyachi Y
J Hepatobiliary Pancreat Surg; 2001; 8(5):473-8. PubMed ID: 11702259
[TBL] [Abstract][Full Text] [Related]
9. [Usefullness of scintigraphy with somatostatin analogues in the imaging of insulinoma of the pancreas].
Owecki M; Czepczyriński R; Biczysko M; Stawny B; Drews M; Sowiński J
Pol Merkur Lekarski; 2006 Jan; 20(115):77-80. PubMed ID: 16617742
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors.
Krausz Y; Bar-Ziv J; de Jong RB; Ish-Shalom S; Chisin R; Shibley N; Glaser B
Am J Gastroenterol; 1998 Jan; 93(1):66-70. PubMed ID: 9448177
[TBL] [Abstract][Full Text] [Related]
11. Value of SPET/CT image fusion in the assessment of neuroendocrine tumours with 111In-pentetreotide scintigraphy.
Moreira AP; Duarte LH; Vieira F; João F; Lima JP
Rev Esp Med Nucl; 2005; 24(1):14-8. PubMed ID: 15701341
[TBL] [Abstract][Full Text] [Related]
12. 111In-pentetreotide (somatostatin analogue) scintigraphy as an imaging procedure for endocrine gastro-entero-pancreatic tumors.
Nauck C; Ivancević V; Emrich D; Creutzfeldt W
Z Gastroenterol; 1994 Jun; 32(6):323-7. PubMed ID: 7975760
[TBL] [Abstract][Full Text] [Related]
13. Combined Indium-111 octreotide scintigraphy and low-dose computed tomography in localization of neuroendocrine tumors.
Kjaer A; Dreyer M
Clin Nucl Med; 2003 Jun; 28(6):506-8. PubMed ID: 12917538
[No Abstract] [Full Text] [Related]
14. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours.
Chiti A; Briganti V; Fanti S; Monetti N; Masi R; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):42-9. PubMed ID: 10932600
[TBL] [Abstract][Full Text] [Related]
15. Intraoperative gamma probe detection of neuroendocrine tumors.
Adams S; Baum RP; Hertel A; Wenisch HJ; Staib-Sebler E; Herrmann G; Encke A; Hör G
J Nucl Med; 1998 Jul; 39(7):1155-60. PubMed ID: 9669386
[TBL] [Abstract][Full Text] [Related]
16. 111Indium pentetreotide imaging in the evaluation of head and neck tumors.
Myssiorek D; Tronco G
Laryngoscope; 2005 Oct; 115(10):1707-16. PubMed ID: 16222183
[TBL] [Abstract][Full Text] [Related]
17. Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.
Shaverdian N; Pinchot SN; Zarebczan B; Gillis HC; Schiro A; Chen H
Ann Surg Oncol; 2013 Feb; 20(2):640-5. PubMed ID: 22941169
[TBL] [Abstract][Full Text] [Related]
18. [Significance of false-positive findings of somatostatin receptor scintigraphy in diagnosis of neuroendocrine tumors of the gastroenteropancreatic system].
Faiss S; Scherübl H; Bäder M; Fett U; Koppenhagen K; Wiedenmann B; Riecken EO
Z Gastroenterol; 1994 May; 32(5):243-6. PubMed ID: 7915450
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
[TBL] [Abstract][Full Text] [Related]
20. Radiolabeled somatostaitin analogs in the treatment of neuroendocrine tumors: experience of the National Cancer Institute of Milano using high dose of 111In-pentetreotide in metastatic neuroendocrine gastroenteropancreatic tumors.
Bombardieri E; Seregni E; Savelli G; Villano C; Castellani MR; Cirillo F; Pallotti F; Fracassi S; Chiesa C; Chiti A; Bajetta E
J Endocrinol Invest; 2003; 26(8 Suppl):63-9. PubMed ID: 15233216
[No Abstract] [Full Text] [Related]
[Next] [New Search]